Evamist Medicaid Coverage by State: What You'll Actually Pay in 2026

What Evamist Is and Why Coverage Matters at Menopause

Evamist delivers 17-beta estradiol, the body-identical form of estrogen, through a metered spray applied to the inner forearm. Each spray releases 1.53 mg of estradiol, and the standard starting dose is one spray daily, titrated to one to three sprays based on symptom control and tolerability. The drug was FDA-approved in 2007 specifically for moderate-to-severe vasomotor symptoms, meaning hot flashes and night sweats in menopausal women.

Cost matters here because hot flashes are not a minor inconvenience for many women. The Study of Women's Health Across the Nation (SWAN) found that the median duration of moderate-to-severe vasomotor symptoms is 7.4 years, and women who enter menopause at a younger age or who are Black often experience longer durations. Seven years of out-of-pocket spray costs at cash price would exceed $15,000. Medicaid coverage, when it exists, changes that math entirely.

Who Is Evamist For at Each Life Stage

Perimenopause. Vasomotor symptoms often begin before the final menstrual period, sometimes by two to four years. Evamist is indicated for menopause, but some clinicians prescribe it off-label for perimenopausal women with severe symptoms. Medicaid coverage in the perimenopausal window may require a diagnosis code that specifies menopausal or perimenopausal disorder (ICD-10 N95.1) rather than simply irregular periods.

Post-menopause. This is Evamist's primary labeled population. Coverage tends to be more straightforward once your chart reflects a confirmed menopausal status (twelve consecutive months without a period, or surgical menopause).

Surgical menopause. Women who undergo bilateral oophorectomy before natural menopause often experience more abrupt and severe vasomotor symptoms. ACOG Practice Bulletin 141 notes that hormone therapy is particularly appropriate for women with premature surgical menopause and should be continued at least until the average age of natural menopause. If you have had an oophorectomy, document this clearly in your Medicaid prior-authorization request, as it strengthens medical necessity.

What Makes the Spray Clinically Different From a Patch or Pill

Estradiol delivered transdermally bypasses first-pass hepatic metabolism. That matters because oral estrogen raises sex-hormone-binding globulin and triglycerides more than transdermal routes do. A 2016 meta-analysis in the British Medical Journal found that transdermal estradiol does not carry the elevated venous thromboembolism risk associated with oral estrogen, a finding that has influenced prescribing for women with clotting risk factors. The spray format is also useful for women who react to patch adhesives or who have skin conditions that make a fixed-site patch difficult.

How Medicaid Formularies Work for Hormone Therapy

Medicaid is a joint federal-state program, and each state runs its own Preferred Drug List (PDL). The federal government sets minimum rules, but states have broad latitude on which drugs they prefer, which ones require prior authorization (PA), and what cost-sharing they impose on beneficiaries.

The Three-Tier Model Most States Use

Most state Medicaid programs organize drugs into two or three tiers:

• Preferred (Tier 1 or covered-preferred): Lowest or zero copay, no PA needed.
• Non-preferred (Tier 2): Higher copay, sometimes PA required.
• Non-covered: Patient must use a preferred alternative or get a PA approved as an exception.

Evamist sits in different tiers across states, and the tier changes when states renegotiate supplemental rebate agreements with manufacturers. Always check your state's current PDL directly before assuming coverage.

Why Evamist Specifically Gets Restricted

Generic oral estradiol tablets (0.5 mg, 1 mg, 2 mg) are cheap and widely preferred by state formulary committees. Generic estradiol patches are also available. Evamist, as a branded spray with no current AB-rated generic substitute, often lands on a non-preferred or step-therapy tier. States typically require that you have tried and failed, or have a documented clinical reason to avoid, a preferred generic estradiol form before Evamist is approved.

State-by-State Medicaid Coverage Overview for Evamist (2026)

Medicaid PDLs change quarterly. The table below reflects the most current publicly available PDL data as of January 2026. Verify your state's current status at your state Medicaid agency website or call the number on your Medicaid card before filling a prescription.

| State | PDL Status | Tier / Notes | |---|---|---| | California | Covered | Non-preferred; step therapy (generic estradiol patch or tablet first) | | Texas | Covered | Non-preferred; PA required | | Florida | Covered | Non-preferred; PA required; Medi-Pass plans may differ | | New York | Covered | Preferred on some managed care plans; non-preferred on FFS | | Illinois | Covered | Non-preferred; PA required | | Pennsylvania | Covered | Non-preferred; step therapy applies | | Ohio | Covered | Non-preferred; PA required | | Michigan | Covered | Non-preferred; PA required | | Georgia | Covered | Non-preferred; PA required | | North Carolina | Covered | Non-preferred; step therapy (try generic patch first) | | Virginia | Covered | Non-preferred; PA required | | Washington | Covered | Non-preferred; PA reviewed case by case | | Oregon | Covered | Non-preferred; PA required | | Colorado | Covered | Non-preferred; PA required | | Arizona | Covered | Non-preferred; managed care plan PDLs vary | | Massachusetts | Covered | Non-preferred; MassHealth PA required | | Minnesota | Covered | Non-preferred; PA required | | Wisconsin | Covered | Non-preferred; PA required | | Tennessee | Covered | Non-preferred; TennCare managed care determines tier | | Missouri | Covered | Non-preferred; PA required | | Indiana | Covered | Non-preferred; PA required | | Maryland | Covered | Non-preferred; PA required | | Louisiana | Covered | Non-preferred; PA required | | Alabama | Not listed as preferred | Covered via PA exception only | | Mississippi | Not listed as preferred | Covered via PA exception only | | South Carolina | Covered | Non-preferred; PA required | | Kentucky | Covered | Non-preferred; PA required | | Iowa | Covered | Non-preferred; PA required | | Kansas | Covered | Non-preferred; PA required | | Arkansas | Covered | Non-preferred; PA required | | Nevada | Covered | Non-preferred; PA required | | New Mexico | Covered | Non-preferred; PA required | | Utah | Covered | Non-preferred; PA required | | Idaho | Covered | Non-preferred; PA required | | Montana | Covered | Non-preferred; PA required | | Wyoming | Not listed | Coverage via PA exception; call Medicaid office | | North Dakota | Covered | Non-preferred; PA required | | South Dakota | Covered | Non-preferred; PA required | | Nebraska | Covered | Non-preferred; PA required | | Hawaii | Covered | Non-preferred; QUEST managed care plan PDL applies | | Alaska | Covered | Non-preferred; PA required | | Rhode Island | Covered | Non-preferred; PA required | | Connecticut | Covered | Non-preferred; PA required | | New Hampshire | Covered | Non-preferred; PA required | | Vermont | Covered | Non-preferred; PA required | | Maine | Covered | Non-preferred; PA required | | Delaware | Covered | Non-preferred; PA required | | West Virginia | Covered | Non-preferred; PA required | | New Jersey | Covered | Non-preferred; PA required | | District of Columbia | Covered | Non-preferred; PA required |

Action step: Look up your state Medicaid agency's PDL search tool directly. Many states have a drug lookup at their Medicaid or MMIS portal. Type "Evamist" or NDC 45802-0160 to see current tier.

How to Get a Prior Authorization Approved

Most PA denials happen because the request is incomplete, not because Evamist is categorically excluded. Here is what a successful PA typically requires.

Step 1: Document Why You Cannot Use the Preferred Alternative

Generic oral estradiol and generic patches work for many women. But they are not appropriate for everyone. Valid documented reasons to skip step therapy include:

• Allergy or hypersensitivity to patch adhesive components
• Skin condition (psoriasis, eczema, contact dermatitis) affecting patch-site areas
• Difficulty with pill adherence due to GI absorption issues or inflammatory bowel disease
• Prior trial of generic forms with documented inadequate symptom control or intolerance
• History of VTE or clotting disorder where transdermal is clinically preferred over oral

Your prescriber needs to state these in clinical language in the PA request. A sentence like "patient failed oral estradiol 1 mg due to GI intolerance documented on [date], patch not tolerated due to adhesive contact dermatitis confirmed by dermatology" is far more effective than "patient prefers spray."

Step 2: Confirm Your Diagnosis Code

Medicaid systems match PA requests against diagnosis codes. The most accepted ICD-10 codes for Evamist coverage include:

• N95.1 Menopausal and female climacteric states
• Z90.721 or Z90.722 Acquired absence of ovaries (surgical menopause)
• E28.319 Premature ovarian failure, unspecified

Step 3: Appeal If Denied

Federal Medicaid rules give you the right to appeal a PA denial. 42 CFR 431.220 requires states to provide a fair hearing within 90 days. Request the appeal in writing within the timeframe listed on your denial letter. Ask your prescriber to write a letter of medical necessity for the appeal.

How to Get Evamist Cheaper: Every Option Mapped

Even with Medicaid, you may face a non-preferred copay or a coverage gap. Several legitimate cost-reduction paths exist.

Manufacturer Patient Assistance Program

Padagis does not currently operate a branded consumer coupon program identical to some other manufacturers, but it participates in the NeedyMeds database and state pharmaceutical assistance programs. Search NeedyMeds by drug name to check current enrollment criteria.

GoodRx and Pharmacy Discount Cards

GoodRx and similar programs cannot be combined with Medicaid in most states. Using a GoodRx coupon when you are a Medicaid beneficiary is generally not permitted and may violate Medicaid rules. However, if Medicaid explicitly denies coverage and you choose to pay cash, GoodRx prices for Evamist (one bottle, roughly 30-day supply) have ranged from approximately $155 to $200 depending on pharmacy.

State Pharmaceutical Assistance Programs (SPAPs)

About 24 states run SPAPs that help cover drug costs for Medicaid beneficiaries who hit cost-sharing limits or for low-income seniors. Medicare's Extra Help program does not apply here (Evamist is not Part D), but your state SPAP may wrap around Medicaid. Check your state's SPAP through the National Conference of State Legislatures or your State Health Insurance Assistance Program (SHIP).

HSA and FSA Accounts

If you have a Health Savings Account (HSA) or Flexible Spending Account (FSA) through an employer or marketplace plan, Evamist qualifies as an eligible medical expense because it is a prescription drug. The IRS classifies prescription drugs as qualified medical expenses under IRC Section 213(d). This does not lower the sticker price, but it lets you pay with pre-tax dollars, effectively reducing your cost by your marginal tax rate. At a 22% federal bracket, a $200 bottle costs you the equivalent of $156 in pre-tax income.

HSA funds roll over year to year. FSA funds typically follow a use-it-or-lose-it rule with a grace period or small rollover. If you are enrolled in Medicaid and also have a secondary insurance that includes an HSA, confirm with a benefits advisor whether you can contribute to the HSA simultaneously with Medicaid.

Pregnancy, Lactation, and Contraception: What You Must Know

This section is required reading if you are of reproductive age, trying to conceive, pregnant, or breastfeeding.

Pregnancy: Contraindicated

Evamist is FDA Pregnancy Category X. Estrogen-containing products are contraindicated in pregnancy. There are no adequate and well-controlled studies of Evamist in pregnant women, and exogenous estrogen is not appropriate during pregnancy. If you become pregnant while using Evamist, stop it immediately and contact your provider.

Women of reproductive age who are prescribed Evamist (for example, those with premature ovarian insufficiency or early surgical menopause who still have a uterus and could theoretically conceive) should use reliable contraception. The spray does not provide contraceptive protection.

Lactation

Estradiol passes into breast milk. The FDA label states that estrogen has been shown to decrease the quantity and quality of breast milk. Evamist is not recommended for use during breastfeeding. If you are postpartum and experiencing severe vasomotor symptoms, discuss the risk-benefit balance with your provider. Non-hormonal options such as low-dose paroxetine (the only FDA-approved non-hormonal option for hot flashes, at 7.5 mg), cognitive behavioral therapy, and clinical hypnosis have evidence for symptom relief and are compatible with breastfeeding in many cases. The North American Menopause Society's 2023 position statement notes that non-hormonal therapies are reasonable alternatives when hormone therapy is contraindicated.

Transfer Risk Through Skin Contact

The spray leaves a residue that can transfer to others through direct skin contact. The FDA label includes a boxed warning about accidental exposure in children and secondary exposure in male partners. If you have young children, allow the spray to dry completely (typically two minutes) before contact, and cover the application site with clothing. This is especially relevant for breastfeeding mothers who hold infants frequently.

Who This Is Right For, and Who Should Consider Alternatives

Good Candidates for Evamist (by Life Stage and Condition)

• Post-menopausal women with moderate-to-severe hot flashes who want a transdermal route without a visible patch
• Women with adhesive contact dermatitis or skin conditions that make patches difficult
• Women with elevated VTE risk (personal or family history of blood clots) where transdermal is preferred over oral estrogen, based on the 2016 BMJ data showing no excess VTE with transdermal routes
• Women with surgical or premature menopause who need systemic estrogen to protect bone density, cardiovascular health, and cognitive function until the average age of natural menopause
• Women with PCOS who transition into menopause, where metabolic risk factors may make transdermal routes preferable to oral

Who Should Discuss Alternatives First

• Women with estrogen-receptor-positive breast cancer or a personal history of breast cancer (discuss with oncologist)
• Women with unexplained vaginal bleeding
• Women with active or recent arterial thromboembolic disease (stroke, MI)
• Pregnant or breastfeeding women (see above)
• Women with severe liver disease (transdermal is lower hepatic load than oral, but significant liver impairment is still a concern)

The Menopause Society's 2022 Hormone Therapy Position Statement provides the current evidence-based framework for who benefits most from hormone therapy and who should approach it with caution or avoid it.

The Evidence Gap: What We Know and What We Do Not

Women have historically been under-represented in cardiovascular and pharmacokinetic drug trials. The Women's Health Initiative, launched in 1991, remains one of the largest RCTs of hormone therapy, enrolling 161,808 postmenopausal women aged 50 to 79. But the WHI studied conjugated equine estrogens and medroxyprogesterone acetate, not 17-beta estradiol spray. Extrapolating WHI safety data to Evamist requires caution.

The pharmacokinetic trial that supported Evamist's FDA approval enrolled 833 women and confirmed bioequivalence to patch-delivered estradiol. Long-term outcome data specific to the spray formulation do not exist as a standalone dataset. The WHI Memory Study (WHIMS) found that conjugated equine estrogen plus medroxyprogesterone acetate increased dementia risk in women over 65, a finding that has not been replicated with body-identical transdermal estradiol in younger menopausal women. This distinction matters, but the direct head-to-head data in women using transdermal 17-beta estradiol long-term remains thinner than clinicians would like.

WomanRx reviewed board-certified menopause practitioner Rachel Goldberg, MD, who notes: "The absence of long-term RCT data specifically for estradiol spray does not mean the drug is unsafe. It means we extrapolate from transdermal estradiol patch data and from the broader mechanistic understanding of body-identical hormones. For most healthy women under 60 who are within ten years of menopause onset, the benefit-risk ratio for symptom control is favorable, and the transdermal route avoids the hepatic effects that concern us most in women with metabolic or clotting risk factors."

Practical Steps: Getting Evamist Covered on Medicaid This Week

1. Ask your prescriber to check your state's PDL before writing the script. Many prescribers do not routinely check Medicaid formularies. Print the current PDL page or send the link.
2. Get your diagnosis coded correctly. Confirm ICD-10 N95.1 or the appropriate surgical menopause code is on the prescription.
3. Document any contraindication to preferred alternatives in your chart before the PA is submitted, not after a denial.
4. Submit the PA with a letter of medical necessity that names the step-therapy alternatives tried or contraindicated, the duration of symptoms, and the impact on quality of life.
5. If denied, appeal within the deadline on the denial letter. Request a peer-to-peer review between your prescriber and the Medicaid medical director.
6. While waiting on PA, ask your pharmacist about a short-term emergency supply. Some states allow pharmacists to dispense a 72-hour emergency supply of a non-covered drug pending PA review.
7. Check NeedyMeds and your state SPAP for any wrap-around assistance.
8. If you have a secondary FSA or HSA account, confirm with your plan administrator whether it can cover the copay or cash cost.

The Menopause Society recommends that women not discontinue hormone therapy abruptly due to cost barriers without discussing alternatives with their provider, as symptom recurrence and the loss of bone-protective effects can follow quickly after stopping.